Immuron

Immuron Ltd. Sponsored ADR is the U.S.-listed depositary receipt for Immuron Limited, an Australian biopharmaceutical company focused on developing and commercializing oral polyclonal antibody products. Immuron’s current portfolio centers on products and programs designed for gastrointestinal and infectious disease applications, including Travelan, an over-the-counter product used to help reduce the risk of traveler’s diarrhea, and Protectyn, an immune supplement marketed for digestive health support. The company also maintains a research and development pipeline built around targeted antibody technologies and clinical-stage candidates for enteric and other gut-mediated conditions. Through its commercial products and clinical programs, Immuron participates in both consumer health and specialty biopharmaceutical markets, serving as a niche player in microbiome-linked and immune-focused therapies.